Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 12 | 2023 | 1198 | 1.430 |
Why?
|
| Lymph Nodes | 4 | 2019 | 256 | 0.870 |
Why?
|
| Genetic Counseling | 1 | 2022 | 41 | 0.740 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2017 | 118 | 0.690 |
Why?
|
| Axilla | 4 | 2019 | 92 | 0.670 |
Why?
|
| Rosaniline Dyes | 1 | 2014 | 8 | 0.470 |
Why?
|
| Coloring Agents | 1 | 2014 | 67 | 0.460 |
Why?
|
| Lymphatic Vessels | 1 | 2014 | 53 | 0.440 |
Why?
|
| Mastectomy | 4 | 2019 | 142 | 0.380 |
Why?
|
| Ultrasonography, Mammary | 3 | 2018 | 61 | 0.290 |
Why?
|
| Mastectomy, Segmental | 2 | 2018 | 93 | 0.250 |
Why?
|
| Lymphedema | 2 | 2017 | 46 | 0.240 |
Why?
|
| Genetic Testing | 2 | 2023 | 120 | 0.230 |
Why?
|
| Nipples | 2 | 2014 | 33 | 0.220 |
Why?
|
| Mammaplasty | 2 | 2014 | 44 | 0.210 |
Why?
|
| Fertility Preservation | 1 | 2023 | 8 | 0.210 |
Why?
|
| Female | 12 | 2023 | 27053 | 0.180 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 2231 | 0.180 |
Why?
|
| Counseling | 1 | 2022 | 132 | 0.180 |
Why?
|
| Biopsy, Large-Core Needle | 2 | 2018 | 33 | 0.180 |
Why?
|
| Neoplasm Staging | 4 | 2015 | 738 | 0.160 |
Why?
|
| Referral and Consultation | 1 | 2022 | 287 | 0.160 |
Why?
|
| Hematoma | 1 | 2018 | 64 | 0.150 |
Why?
|
| Biopsy, Needle | 2 | 2017 | 179 | 0.150 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2018 | 53 | 0.140 |
Why?
|
| Adiposity | 1 | 2019 | 137 | 0.140 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 137 | 0.140 |
Why?
|
| Health Care Costs | 1 | 2018 | 171 | 0.140 |
Why?
|
| Humans | 13 | 2023 | 50419 | 0.140 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 131 | 0.130 |
Why?
|
| Prolactin | 1 | 2015 | 44 | 0.120 |
Why?
|
| Image-Guided Biopsy | 1 | 2015 | 33 | 0.120 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2014 | 31 | 0.120 |
Why?
|
| Middle Aged | 8 | 2018 | 12579 | 0.110 |
Why?
|
| Diabetic Nephropathies | 1 | 2015 | 63 | 0.110 |
Why?
|
| Organ Sparing Treatments | 1 | 2014 | 56 | 0.110 |
Why?
|
| Cytodiagnosis | 1 | 2013 | 41 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 202 | 0.110 |
Why?
|
| Prognosis | 5 | 2018 | 1974 | 0.110 |
Why?
|
| Patient Care Planning | 1 | 2013 | 66 | 0.110 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2013 | 45 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2013 | 90 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2014 | 622 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2014 | 120 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2013 | 403 | 0.090 |
Why?
|
| Kidney | 1 | 2015 | 690 | 0.080 |
Why?
|
| Aged | 7 | 2018 | 9738 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 3233 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2019 | 6274 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2014 | 1030 | 0.070 |
Why?
|
| Lymphatic Metastasis | 2 | 2015 | 221 | 0.050 |
Why?
|
| Adult | 5 | 2018 | 13561 | 0.050 |
Why?
|
| Young Adult | 3 | 2018 | 4075 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 162 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2017 | 2378 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 280 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2019 | 110 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 276 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2019 | 192 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2017 | 5265 | 0.030 |
Why?
|
| Mexico | 1 | 2015 | 35 | 0.030 |
Why?
|
| Albuminuria | 1 | 2015 | 48 | 0.030 |
Why?
|
| Creatinine | 1 | 2015 | 142 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 119 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 955 | 0.030 |
Why?
|
| Diabetic Retinopathy | 1 | 2015 | 44 | 0.030 |
Why?
|
| Touch | 1 | 2013 | 25 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2014 | 41 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2014 | 54 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 122 | 0.030 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2013 | 35 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 446 | 0.030 |
Why?
|
| Adolescent | 2 | 2015 | 6453 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 439 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 1268 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2014 | 170 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 462 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 640 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1152 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1181 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 1601 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1546 | 0.020 |
Why?
|
| Male | 1 | 2015 | 25866 | 0.010 |
Why?
|